Compound: didanosine
SMILES: O=c1nc[nH]c2c1ncn2[C@@H]3O[C@H](CO)CC3
InChIKey: BXZVVICBKDXVGW-NKWVEPMBSA-N
Synonyms: didanosine, 2',3'-Dideoxyinosine, 69655-05-6, DIDEOXYINOSINE, Videx, Videx EC, Inosine, 2',3'-dideoxy-, Didanosina, Didanosinum, ddIno, 2,3-dideoxyinosine, BMY-40900, (-)-didanosine, NSC-612049, NSC 612049, DTXSID6022927, K3GDH6OH08, BMY 40900, CHEBI:490877, NSC612049, BRN 3619529, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one, DTXCID402927, 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one, 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one, 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol, ddI (Antiviral), 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-3H-PURIN-6-ONE, 2',3' Dideoxyinosine, Didanosine EC, 9-((2R,5S)-5-(hydroxymethyl)oxolan-2-yl)-6,9-dihydro-3H-purin-6-one, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one, RefChem:55012, J05AF02, 614-994-4, DDI, 2', 3'-dideoxyinosine, 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one, MFCD00077728, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol, 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-1H-PURIN-6-ONE, 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE, NCGC00090691-03, NCGC00159514-02, Didanosine 100 microg/mL in Acetonitrile, 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one, Hypoxanthine ddN, Didanosinum [INN-Latin], Didanosina [INN-Spanish], D2I, SMR000058576, Videx(TM), Intron A & Videx, CAS-69655-05-6, Videx (TN), PC-SOD+ddI, Dideoxyinosine (DDI), LOA & ddI, ddI & GM-CSF, SR-05000001487, DRG-0016, DDI and rIFN.alpha.2, ddI & sCD4(rsCD4), UNII-K3GDH6OH08, CCRIS 805, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one, Didanosine RS, DS-4152 & ddI, Didanosine CRS, HSDB 6548, Didanosine [USAN:USP:INN:BAN], Didanosine; 2',3'-dideoxyinosine; 9-(2,3-Dideoxy-beta-d-glycero-pentofuranosyl)-1,9-dihydro-6H-purin-6-one, 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine, Didanosine (Videx), Didanosine and Interferon-.alpha.-2, Videx EC(TM)(slow-release capsules), KS-1049, Didanosine (Standard), 2',3'-didesoxyinosin, 2',3'-Dideoxyinosine (AIDS Initiative), ddI & IFN-.alpha., DIDANOSINE [MI], DIDANOSINE [INN], DIDANOSINE [JAN], DIDANOSINE [HSDB], DIDANOSINE [USAN], DIDANOSINE [VANDF], Epitope ID:768739, DIDANOSINE [MART.], SCHEMBL3363, SCHEMBL3364, SCHEMBL3365, 2',3'-Dideoxy-D-inosine, CHEMBL1460, DIDANOSINE [USP-RS], DIDANOSINE [WHO-DD], DIDANOSINE [WHO-IP], 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine, Listera ovata agglutinin & 2',3'-Dideoxyinosine, Didanosine (JAN/USP/INN), MLS000759469, MLS001055350, MLS001424118, MLS002154216, MLS006011561, GTPL4833, orb1305302, SCHEMBL7866996, DIDANOSINE [EP IMPURITY], DIDANOSINE [ORANGE BOOK], SCHEMBL29387997, Didanosine for system suitability, HY-B0249R, 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein), DIDANOSINE [EP MONOGRAPH], DIDANOSINE [USP IMPURITY], DIDANOSINE [USP MONOGRAPH], GLXC-08098, HMS2051J11, HMS2089N20, HMS2095O08, HMS2232P22, HMS3712O08, HMS3884M06, DIDANOSINUM [WHO-IP LATIN], HY-B0249, Didanosine for system suitability RS, Tox21_111732, Tox21_202333, Tox21_300575, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one, BDBM50404252, EBC-13588, EBC-26267, EBC-44229, Didanosine for system suitability CRS, 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor, 2',3'-DIDEOXYINOSINE; Didanosine, AKOS015833088, AKOS015901454, AKOS015963259, AKOS026750545, Tox21_111732_1, CCG-100947, CCG-220153, DB00900, NC00197, ND02929, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one, SRI-7013-04, SRI-7013-05, SRI-7013_07, NCGC00090691-01, NCGC00090691-02, NCGC00090691-14, NCGC00159514-03, NCGC00159514-04, NCGC00164280-01, NCGC00188983-01, NCGC00254496-01, NCGC00259882-01, NCGC00390773-01, 2DI, AC-12026, AC-32186, BP-58651, SMR004703324, 2',3'-Dideoxyinosine, >=98% (HPLC), 2',3'-Dideoxyinosine & Interferon-.alpha., D3066, NS00000541, SW198619-2, C06953, D00296, EN300-123032, T71244, F326235, Q422606, SR-05000001487-1, SR-05000001487-2, BRD-K99063460-001-12-3, BRD-K99063460-001-13-1, Z1546616193, Didanosine, European Pharmacopoeia (EP) Reference Standard, Didanosine, United States Pharmacopeia (USP) Reference Standard, Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2, Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-, 9-[(2R,5S)-5-(Hydroxymethyl)oxolan-2-yl]-1,9-dihydro-6H-purin-6-one, 9-((2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE, Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard, 2',3'-Dideoxy-1,9-dihydro-9-beta- D -ribofuranosyl-6 H -purin-6-one; 2',3'-Dideoxyinosine;
Theoretical properties:
molecular_formula: C10H12N4O3
molecular_weight: 236.23 g/mol
exact_mass: 236.09094026 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 2
heavy_atom_count: 17
topological_polar_surface_area: 88.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White solid
color: White solid
melting_point: 347 °F (decomposes) (NTP, 1992)
solubility: 10 to 50 mg/mL at 70 °F (NTP, 1992)
vapor_pressure: 6.6 mm Hg @ 25 °C /Estimated/
Descriptions:
pubchem: Didanosine is a purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS. It has a role as a geroprotector, an antimetabolite, an antiviral drug, a HIV-1 reverse transcriptase inhibitor and an EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor.
chebi: A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.
chembl: DIDANOSINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Didanosine, sold under the brand name Videx among others, is a medication used to treat HIV/AIDS. It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class.
Didanosine was first described in 1975 and approved for use in the United States in 1991.